Alpha-Klotho is a member of the Klotho family consisting of two other single-pass transmembrane proteins: βKlotho and γKlotho; αKlotho has been shown to circulate in the blood. Fibroblast growth factor (FGF)23 is a member of the FGF superfamily of 22 genes/proteins. αKlotho serves as a co-receptor with FGF receptors (FGFRs) to provide a receptacle for physiological FGF23 signaling including regulation of phosphate metabolism. The extracellular domain of transmembrane αKlotho is shed by secretases and released into blood circulation (soluble αKlotho). Soluble αKlotho has both FGF23-independent and FGF23-dependent roles in phosphate homeostasis by modulating intestinal phosphate absorption, urinary phosphate excretion, and phosphate distribution into bone in concerted interaction with other calciophosphotropic hormones such as PTH and 1,25-(OH) 2 D. The direct role of αKlotho and FGF23 in the maintenance of phosphate homeostasis is partly mediated by modulation of type II Na + -dependent phosphate co-transporters in target organs. αKlotho and FGF23 are principal phosphotropic hormones, and the manipulation of the αKlotho-FGF23 axis is a novel therapeutic strategy for genetic and acquired phosphate disorders and for conditions with FGF23 excess and αKlotho deficiency such as chronic kidney disease.
Introduction
Alpha-Klotho (αKlotho) and fibroblast growth factor (FGF)23 were independently discovered in 1997 [52] and 2000 [19] and were labeled as an anti-aging protein and a novel phosphaturic hormone, respectively. Interestingly, the FGF23-null mouse phenocopies almost all features observed in αKlotho-null mouse including short lifespan, hyperphosphatemia, and ectopic calcification, suggesting that αKlotho and FGF23 might share common downstream pathways, at least in the maintenance of phosphate (Pi) metabolism [75] . Shortly after, two research laboratories independently confirmed that membrane αKlotho functions as a mandatory co-receptor for FGF23 and along with the FGF receptor (FGFR) to transduce FGF23 signaling to modulate Pi metabolism as a phosphotropic hormone [53, 95] .
The extracellular domain of membrane αKlotho can be shed by secretases and released into the circulation and urine [8, 15, 42, 44, 97] . This cleaved αKlotho protein is hereinafter referred as soluble αKlotho. Recently, a different model was presented where soluble αKlotho can also sustain FGF23 signaling by acting as a deliverable coreceptor [16] . The current model of this complex based on the crystal structure is a 2:2:2 ternary complex of αKlotho, FGFR1c, and FGF23. In this complex, αKlotho simultaneously tethers the D3 domain of FGFR1c and FGF23 via the FGF23 C-terminal tail, thus implementing FGF23-FGFR1c proximity and conferring stability. This model does not formally exclude other possibilities that other higher ratios of this complex or soluble αKlotho alone can exert as a functional unit for Pi metabolism.
The SLC34 family of type II Na + -driven Pi co-transporters (NaPi) includes NaPi-2a, NaPi-2b, and NaPi-2c. Both NaPi-2a and NaPi-2c are mainly expressed in renal tubules [26, 27, 61] and NaPi-2b in more widely distributed tissues including intestinal epithelial apical membrane [73, 74, 88] . Type II NaPi cotransporters are primary regulators in the maintenance of Pi balance [100] . This review updates recent progress in the knowledge of the physiological role of αKlotho and FGF23 in modulation of epithelial NaPi-2a, NaPi-2b, and NaPi-2c, although there is evidence showing both αKlotho and FGF23 regulate type III Na-Pi co-transporters (PIT-1 and PIT-2) [9, 39, 93, 99 ]; this will not be addressed in this review.
FGF23, FGFR, and αKlotho expression and regulation

FGF23 expression
The FGFs are a highly conserved superfamily of genes divided into seven subfamilies. FGFs exert pleiotropic effects on extremely broad biological processes, including development, organogenesis, and metabolism, through binding and activation of FGFR tyrosine kinases [40] . The three members FGF23, FGF21, and FGF19/15 constitute the endocrine FGF19 family.
FGF23 is a genuine osteogenic endocrine hormone, primarily secreted from the bone (osteocytes and osteoblasts) and has a myriad of effects, and it acts on the kidney to promote phosphaturia and suppression of active vitamin D (1,25-dihydroxyvitamin D 3 , 1,25-(OH) 2 D) synthesis and intestinal Pi absorption, thereby promoting negative external Pi balance [40] . FGF23 is a 32-kDa 251-amino acid glycoprotein with a signal sequence (24 amino acids), an N-terminal FGF core homology domain (155 amino acids), and a C-terminal domain (72 amino acids) unique to FGF23 [5, 40, 68, 80] . The C-terminal domain is essential for interaction with and activating the FGFR-Klotho complex [16] . Between the N-and C-terminal domains is a proteolytic site (176 RXXR 179), and FGF23 is inactivated by subtilisin-like proprotein convertase and plasminogen activators, resulting in two inactive N-and active C-terminal fragments [10, 21-23, 43, 72, 90, 102] . The C-terminal fragment can competitively interfere the formation of intact FGF23/αKlotho/FGFR complex, thus acting as a natural FGF23 antagonist [34] .
FGFR expression
FGFRs are single-pass receptor tyrosine kinase transmembrane proteins. There are four cell surface FGFR isoforms (FGFR1-FGFR4 with further subdivision from splice variants), which are ubiquitously expressed but differentially activated by different FGF ligands in conjunction and complexed with heparan sulfate proteoglycan and with αKlotho and βKlotho [16, 40, 56] . Because of universal expression of FGFRs and restricted expression of membrane αKlotho, tissue specificity of FGF23 action is proposed to be conferred by the presence of transmembrane αKlotho protein through formation of the FGFR/FGF23/αKlotho tertiary complex [16, 40, 56] .
Although soluble αKlotho and FGF23 are present in the circulation and soluble αKlotho is also able to form similar complex as membrane αKlotho [16] , distinct expression pattern of FGFR isoforms and their different affinities of binding to αKlotho may provide a certain degree of specificity to FGF23 action. αKlotho expression αKlotho is predominantly expressed in renal distal convoluted tubules with lower abundance in proximal convoluted tubules and in parathyroid chief cells, making the kidney and parathyroid gland the primary FGF23 target organs for mineral metabolism [4, 38] . In addition to the kidney and parathyroids, αKlotho is also present in osteocytes and osteoblasts, which regulates FGF23 synthesis [46, 50] . To date, there is no evidence showing the presence of αKlotho in the intestinal epithelium, another crucial organ regulating Pi absorption. Animal experiments showed that administration of FGF23 protein increases membrane αKlotho in the parathyroid gland [4] and in the kidney with an increase in soluble αKlotho [91] .
The transmembrane αKlotho protein does not only constitute the cellular basis for initiation of FGF23 signal in specific tissues but also provides circulating soluble αKlotho which can reduce serum Pi and suppress the secretion of PTH and 1,25-(OH) 2 D [94] , thus indirectly influencing the production of FGF23. FGF23 and αKlotho can reciprocally modulate each other to both directly and indirectly participate in Pi homeostasis (Fig. 1 ).
αKlotho and FGF23 action on phosphate transport in the kidney, intestine, and bone Pi is vital for many biological functions including energy metabolism, intracellular signaling, structural composition of many cellular components, and bone mineralization. Pi homeostasis is regulated by the coordinated interplay of different organs including the intestine, kidney, and bone, and endocrine networks consisting of PTH, 1,25-(OH) 2 D, FGF23, and αKlotho ( Figs. 1 and 2) .
Type II Na + -dependent Pi co-transporters (NaPi-2) are responsible for active uptake of extracellular Pi into polarized epithelial cells [6, 61, 63, 79] . NaPi-2a and NaPi-2c are expressed in apical brush border membranes (BBMs) of the renal proximal tubules and play a major role in active Pi reabsorption in the kidney [12, 60, 98] , and NaPi-2b present in the luminal membrane of the ileum mediates active Pi absorption in the intestine [37, 78] (Table 1) . Type III co-transporters including PIT-1 and PIT-2 are expressed broadly. PIT-1 exists in the bone and kidney and PIT-2 in the intestine and bone. They participate in Pi absorption in the intestine, Pi reabsorption in the kidney, and cellular uptake of Pi, and Pi release and storage in the bone [27, 63, 79, 101] . The role and regulation of PIT-1 and PIT-2 are not discussed in this manuscript.
Pi balance is achieved through modulation of intestinal uptake of Pi from diet, renal excretion of Pi from urine, and bone Pi uptake/release via regulation of expression and activity or several Na + -coupled Pi transporters. One interesting difference between the kidney and the intestine is the mirror image of the distribution of transcellular and paracellular transport of calcium and phosphate. Calcium absorption is exclusively transcellular in the gut and mostly paracellular in the kidney. In contrast, phosphate absorption is exclusively transcellular in the kidney and largely paracellular in the gut. Both active Na + -dependent transcellular Pi and passive paracellular Pi transport occur across the apical membrane in the intestine [79] . Both FGF23 and αKlotho regulate Na + -dependent Pi transport across the apical membrane [3, 30, 41] (Fig. 2 ), but the mechanism of Pi efflux across the basolateral membrane remains to be identified.
FGF23/αKlotho effect on renal phosphate reabsorption
In the kidney, NaPi-2a and NaPi-2c expression and function in proximal tubules have been well characterized ( Table 1 , Fig. 2 ). High-Pi diet causes gradual downregulation of Pi reabsorption mediated by a decrease in NaPi-2a (< 1 h) followed by delayed and eventual downregulation of PiT-2 (> 8 h) and NaPi-2c (> 24 h) in normal rats [65] . Table 1 αKlotho and FGF23 inhibit NaPi-2a, NaPi-2b, and NaPi-2c expression and activity NaPi-2 in the kidney NaPi-2 in the gut
S refers to the segment of the renal proximal tubule, which is subdivided into three segments: S1, the first portion of the proximal convoluted tubule; S2, the latter portion of the proximal convoluted tubule and the first portion of the proximal straight tubule; and S3, the latter portion of the proximal straight tubule Fig. 2 The role of αKlotho, PTH, FGF23, and 1,25-(OH) 2 D in the modulation of NaPi-2a, NaPi-2b, and NaPi-2c. Phosphate absorption from small intestine is mainly controlled by NaPi-2b, which is negatively regulated by soluble αKlotho and probably FGF23 (dash line), but positively by 1,25-(OH) 2 D. Urinary Pi excretion through the kidney is mainly controlled by NaPi-2a and NaPi-2c. Their expression and activity are negatively regulated by several calciophosphotropic hormones (PTH, FGF23, and soluble αKlotho). Pi flux in the bone contributing to Pi homeostasis is presumably suppressed by FGF23 in an autocrine manner as well as soluble αKlotho (dash line) but awaits to be proved. Dash line: putative effect yet to be experimentally confirmed. Solid line: experimentally confirmed results FGF23, as a phosphaturic hormone, leads to negative Pi balance by reducing the expression of NaPi-2a and NaPi-2c in the renal proximal tubule and by reducing serum 1,25-(OH) 2 D levels [3, 30, 31 ]. An important study by Baum et al. used isolated tubules from Hyp mice with high FGF23 levels and showed that the decreased Pi transport can recover in vitro with time accompanied by increased apical membrane NaPi-2a after removal of the tubule from the high FGF23 Hyp milieu, and the recovery can transpire in the absence of translation [3] . This finding suggests that FGF23 maintains a tonic shift of NaPi-2a away from the cell surface. Between FGFR3 and R4 global null mice, and in conditional renal tubular FGFR1-null mice, there were no differences in serum Pi levels, and NaPi-2a and NaPi-2c expression in the renal brush border membrane vesicles (BBMVs) compared to their WT littermates. Administration of FGF23 to FGFR3-null mice or FGFR4-null mice induced hypophosphatemia and a decrease NaPi-2a and NaPi-2c protein expression in renal BBMVs. In contrast, injection of FGF23 into FGFR1-null mice had no effect on serum phosphorus levels or NaPi-2a and NaPi-2c expression in BBMVs, indicating FGFR1 is the principal receptor for FGF23 to induce hypophosphatemia, while FGFR4 is a minor player [30] .
αKlotho deficiency upregulates NaPi-2a expression in the kidney and NaPi transport activity [66, 83] . Increasing αKlotho in the kidney and urine chronically by transgenic overexpression of αKlotho or acutely by intravenous infusion of αKlotho caused hypophosphatemia, phosphaturia from decreased proximal phosphate reabsorption, and decreased activity and protein of the principal renal phosphate transporter NaPi-2a. In addition, αKlotho deficiency is associated with upregulation of NaPi-2c in the kidney [83] , which should exacerbate hyperphosphatemia in αKlotho-deficient mice. However, those intact animal experiments cannot discern direct vs. indirect effect of αKlotho on modulation of renal NaPi transport.
Direct inhibition of NaPi-2a by αKlotho was shown in cultured cells and in cell-free membrane vesicles characterized by acute inhibition of Na-dependent Pi transport activity followed by decreased cell surface protein [38] . The Pi transport inhibition can be mimicked by recombinant β-glucuronidase and is associated with proteolytic degradation and reduced surface NaPi-2a. The inhibitory effect of αKlotho on NaPi-2a was blocked by β-glucuronidase inhibitor but not by protease inhibitor, suggesting that one mechanism of αKlotho-induced phosphaturia is enzymatic action on the proximal tubule urinary lumen through modifying glycans (not on NaPi-2a), consequently decreasing transporter activity, promoting NaPi-2a proteolytic degradation possibly followed by internalization of NaPi-2a from the apical membrane [38] .
FGF23/αKlotho effect on intestinal phosphate absorption
Functional NaPi-2b is present in the ileum in mice [62] and is thought to be most active in modulating intestinal transcellular Pi absorption. Under physiological conditions, dietary Pi is absorbed in the small intestine by two distinct mechanisms: paracellular transport, which is dependent on electrochemically driven passive diffusion, and transcellular transport, which takes place through NaPi-2b. Genetic deletion of NaPi-2b gives rise to low absorption of dietary Pi, suggesting that NaPi-2b contributes to the maintenance of systemic Pi homeostasis [78] .
In normal mice fed with normal chow, injection of FGF23 plasmids [64] or recombinant protein [34] decreased intestinal Na + -dependent Pi transport activity and the amount of NaPi2b protein in BBMVs [64] and consequently reduced serum Pi. To test the effect of FGF23 on plasma Pi reduction through modulation of intestinal NaPi-2b, Tomoe and colleagues [93] treated WT mice and NaPi-2a , suggesting that FGF23 is not able to further inhibit intestinal NaPi-2b expression and intestinal Pi absorption when there is renal Pi wasting and low 1,25(OH) 2 D, which are known stimulators of NaPi-2b expression [28] (Fig. 2) . However, it has not been established whether FGF23-reduced NaPi-2b is associated with decreased 1,25(OH) 2 D synthesis. In the presence of significant paracellular Pi transport [79] , it may be difficult to evaluate the effect of modulation of NaPi-2b activity on intestinal Pi transport. αKlotho-deficient mice displayed an increased activity of intestinal NaPi transport and increased levels of NaPi-2b protein compared with WT mice [83] , indicating that upregulation of NaPi-2b protein and activity may be one of the molecular mechanisms of hyperphosphatemia in αKlotho-deficient mice. In vivo studies could not provide convincing evidence supporting a direct effect of αKlotho on NaPi-2a. DermakuSopjani and coworkers [20] used electrophysiologic approaches to determine Pi-induced current and found αKlotho decreased maximal Pi-induced current in both NaPi-2a-and NaPi-2b-expressing Xenopus oocytes. Treatment of NaPi-2a-or NaPi-2b-expressing oocytes with αKlotho protein similarly decreased Pi-induced current [20] . Therefore, αKlotho can directly downregulate intestinal NaPi2b-mediated Pi absorption as well as renal NaPi-2a-mediated Pi reabsorption (Fig. 2) .
FGF23/αKlotho effect on the phosphate transport in the bone
Both NaPi-2a and NaPi-2b were recently found in osteoblastlike cell lines and may play a role in Pi flux to modulate mineralization, but in vivo confirmation is not available [59] . Their responses to Pi challenge differ, as Pi supplementation only upregulated NaPi-2a, and not NaPi-2b, whereas Pi deprivation did not change either one. Therefore, these isoforms may play distinct roles in Pi trafficking across the bone individually, or in concert at different scenarios. Whether FGF23 and αKlotho modulate NaPi-2a and NaPi-2b in the bone remains to be explored (Fig. 2) .
In addition to mechanical support, bone also contributes to the maintenance of circulating Pi and calcium as the largest exchangeable depot; the target organ of several calciophosphotropic hormones such as 1,25-(OH) 2 D, PTH, FGF23, and αKlotho; and the source of FGF23 (Fig. 1) . It has been well established that bone is not only a source of FGF23 but also a target of FGF23 to participate Pi homeostasis [58] . High FGF23 is associated with bone demineralization, osteoporosis, and fractures [17, 18, 49, 105] , suggesting FGF23 can act as a mineralization inhibitor by controlling Ca and Pi entrance and deposit in the bone. In general speaking, FGF23 action on bone has systemic and local modes [69, 82] . Obviously, FGF23 can modulate PTH, 1,25(OH) 2 D, and αKlotho to regulate Pi entrance to bone and mineralization [81, 89, 96, 104, 105] (Fig. 1) . However, direct action of FGF23 on bone mineralization independent of its effect on systemic Pi homoeostasis has been documented in vitro with cultured rat calvarial cells and osteoblastic MC3T3-E1 cell line [36, 82, 84] , but the mechanism has not been elucidated.
The bone phenotype in αKlotho-deficient mice has been recognized for nearly two decades [52] . Mice with αKlotho deficiency have osteopenia characterized by low turnover [47, 48, [106] [107] [108] . However, bone phenotypes can be attributable to either low αKlotho or high FGF23 or high Pi or high 1,25(OH) 2 D or their combinational effect. In vitro studies with human bone marrow mesenchymal stem cells provide convincing evidence which supports the direct effect of αKlotho on osteogenesis [110] . Zhang et al. [110] found that soluble αKlotho protein promoted proliferation of human bone marrow mesenchymal stem cells, decreased expression of osteoblastspecific genes (Runx, ALP, and Col1a1), and calcium deposition as well as FGFR1 expression. Unfortunately, this study did not measure Pi flux in human bone marrow mesenchymal stem cells. Therefore, whether αKlotho modulates Pi uptake by osteoblasts/osteocytes is still not entirely elucidated.
Molecular mechanisms of αKlotho and FGF23 effect on type II NaPi co-transporters
The three members of SLC34 family of Na + -driven phosphate co-transporters, NaPi-2a, NaPi-2b, and NaPi-2c, mediate the translocation of divalent Pi (HPO 4 2− ) together with two (NaPi2c) or three Na + (NaPi-2a and NaPi-2b), respectively. No matter where they are predominantly expressed, the abundance and activity of these transporters are mostly regulated by changes in their expression at the cell surface and are determined by interactions with proteins involved in scaffolding, trafficking, or intracellular signaling. All three transporters are regulated by factors including dietary Pi status and hormones like PTH, 1,25-(OH) 2 D, FGF23, or αKlotho [100] .
Indirect effects of FGF23 and αKlotho on NaPi-2 via PTH and 1,25-(OH) 2 D
The phosphoregulatory factors interact with each other so it is often difficult to discern the direct vs. indirect effects of a certain regulator of Pi metabolism. It is well documented that FGF23 production is regulated by dietary Pi intake, serum Pi, 1,25-(OH) 2 D, PTH, and αKlotho [31, 33, 71, 85, 86] (Fig. 1) . The concept that FGF23 targets FGFRs through formation of a tertiary complex with membrane αKlotho protein to inhibit renal Na-dependent Pi transport activity and 1,25-(OH) 2 D production in the kidney is challenged by in vitro experiments showing that supraphysiologic concentrations of soluble αKlotho protein is able to form similar complex as membrane αKlotho probably to transduce FGF23 signal [16] . However, there is no in vivo experiment to confirm whether soluble αKlotho/FGF23/FGFR1 complex formation is mandatory or a unique way for soluble αKlotho protein to modulate mineral metabolism.
FGF23 inhibits PTH production
FGF23 can act via secondary effects of modulation of PTH. PTH is a phosphaturic hormone, and its synthesis by parathyroid chief cells is regulated by the interplay between FGF23 and normal presence of membrane αKlotho and FGFR1 [4, 72] (Fig. 1) . PTH reduces tubular Pi reabsorption through promoting endocytosis of NaPi-2a and NaPi-2c in the proximal tubule, thus increasing urinary Pi excretion [7, 25, 32] . PTH also stimulates bone turnover and release of calcium and phosphate, enhances intestinal absorption of calcium and phosphate, and increases renal calcium reabsorption while decreasing urinary phosphate reabsorption [55] . High PTH can stimulate the secretion of FGF23 and 1,25-(OH) 2 D and [11, 72] , which increases intestinal Pi absorption (Fig. 2) . While FGF23 inhibits PTH production, PTH stimulates FGF23 production in the bone, completing negative and positive feedback loops (Fig. 1) .
FGF23 inhibits 1,25-(OH) 2 D synthesis
FGF23-null mice have high 1,25-(OH) 2 D, indicating that FGF23 is a 1-α-hydroxylase suppressor [75] (Fig. 1) . In WT mice, FGF23 reduces serum Pi and 1,25-(OH) 2 D and NaPi-2b protein in intestinal BBMVs [64] . In vitamin D receptor (VDR)-null mice prior to FGF23 administration, there was low serum Pi-, Ca-, and Na + -dependent Pi transport activity and NaPi-2b protein in the gut, and higher serum PTH and 1,25-(OH) 2 D levels compared to WT mice. After injection of FGF23 plasmids, VDR-null mice had no change in Na + -dependnet Pi transport activity and NaPi-2b protein. So, FGF23-induced modulation of NaPi-2b activity and protein is mediated through reduction of 1,25-(OH) 2 D [64] . Therefore, FGF23 inhibits 1,25-(OH) 2 D synthesis, consequently reducing intestinal NaPi transport activity and NaPi2b protein levels [64] (Figs. 1 and 2 ). Whether FGF23 can directly suppress NaPi-2b is to be explored.
αKlotho inhibits 1,25-(OH) 2 D synthesis Serum 1,25-(OH) 2 D levels are dramatically increased in αKlotho-deficient mice, suggesting that 1,25-(OH) 2 D synthesis in the kidney be suppressed by αKlotho [52, 109] . Active vitamin D stimulates αKlotho production in the kidney and soluble αKlotho [54, 70, 76] , which consequently suppresses Pi reabsorption (Fig. 2) . Independent of changes in intestinal calcium absorption and serum calcium, 1,25-(OH) 2 D represses transcription of PTH and decreases renal Pi excretion [51] . High vitamin D also increases FGF23 levels to counteract PTH effect on limiting phosphate excretion [70] .
Taken together, almost all players implicated in Pi homeostasis including PTH, 1,25(OH) 2 D, FGF23, and αKlotho that regulate phosphate metabolism independently but are also highly interrelated through modulation of other hormones' metabolism ( Figs. 1 and 2 ).
Direct effects of αKlotho and FGF23 on type II Na-dependent Pi co-transporters
The FGF23-αKlotho co-receptor model
The strikingly similar physical, morphological, and biochemical phenotypes of FGF23-and αKlotho-deficient mice suggested that they may share common signaling pathways [67] . In vivo study further showed that FGF23 injection induces low serum Pi in both WT and FGF23-null mice, but not in FGF23/ αKlotho double-knockout mice or αKlotho knockout alone, suggesting that FGF23 regulation of Pi metabolism depends on the presence of αKlotho [67] . In vitro studies from two laboratories independently confirmed the formation of FGF23/αKlotho/FGFR1 [53, 95] . Hyp mice bearing a mutation of PHEX have higher FGF23, severe hypophosphatemia due to urinary Pi wasting. Deletion of αKlotho causes severe hyperphosphatemia and increased renal NaPi-2a protein expression in Hyp mice despite high serum FGF23. Interestingly, injection of bioactive PTH downregulated renal NaPi-2a and consequently reduced serum Pi in Hyp/αKlotho −/ − mice. These results suggest that in the absence of αKlotho, FGF23 is unable to regulate systemic Pi homeostasis [66] .
FGF23-independent effects of αKlotho
In general, type II NaPi co-transporter activity is regulated through down-or upregulationofabundanceoftheirproteinandtrafficking to and from the cell membrane, but not through change in their mRNA, suggesting post-transcriptional and protein distribution control. Soluble αKlotho suppresses NaPi transport activity, when directly added to cultured proximal tubule-like cells and even in cell-free BBM vesicles without the possibility of protein trafficking, suggesting a direct gating effect on NaPis which is unique for regulators of NaPi-2a and NaPi-2c. A second important finding is that the cell culture and the BBM vesicle experiments did not contain FGF23, indicating that αKlotho exerts an FGF23-independent effect. In support of that notion is the fact that the FGF23-null mice preserve the ability to increase urine Pi excretion in response to exogenous soluble αKlotho [38] .
In addition to the acute direct gating of NaPi co-transporters, the more chronic αKlotho-induced suppression of NaPi transport is associated with reduced surface expression NaPi-2a internalization and degradation through modification of moieties of sugar chain in cell surface protein [38] . The glycan-modifying activity of αKlotho is based on one study with direct measurement [92] and numerous papers using sialidase and glucuronidase inhibitors [1, 13, 14, 38, 57, 103] . However, recently, one in vitro study proposed that soluble αKlotho is unlikely to be a glycan-modifying enzyme [16] . Whether the enzymatic model can be employed to αKlotho effect on NaPi-2a and NaPi-2b in renal proximal tubules remains to be clarified.
αKlotho-independent effects of FGF23
There is suggestion that FGF23 may also directly decease type II NaPi transport activity. To explore its direct effect, Andrukhova and colleagues [2] conducted in vitro experiment with culture proximal tubular cells and dissected proximal tubular segments. They found that FGF23 decreased NaPi-2a protein expression in dissected proximal tubular segments isolated from WT mice. FGF23 at low concentration (< 10 ng/ml) could not, but only at high concentration (> 10 ng/ml), could reduce NaPi-2a protein in proximal tubules isolated from αKlotho-deficient mice, suggesting that perhaps high FGF23 is able to exert αKlotho-independent reduction of NaPi-2a. It is possible that FGF23 at low concentration directly acts on proximal tubular epithelial NaPi-2a through its canonical, αKlotho/ FGFR-dependent signaling pathway. FGF23 at high concentration also directly inhibits NaPi-2a protein in renal tubules through a non-canonical αKlotho-independent signaling pathway [2] , which still needs to be defined. In the heart, FGF23 has been proposed to trans-activate the FGFR4 [35, 77] .
Conclusion and perspectives
Abnormal Pi metabolism is associated with cardiovascular disease and lifespan [24, 29, 45, 87] . The study of the regulation and function of the phosphoregulatory factors FGF23 and αKlotho has led to the great advances in the cellular and molecular mechanisms of Pi homeostasis maintained by an interacting network of hormones including FGF23, αKlotho, PTH, and 1,25-(OH) 2 -VD involving the gut, kidney, bone, and parathyroid glands. The balance of Pi metabolism by modulation of NaPi-2 in the gut, kidney, and bone is important for normal cell metabolism and skeleton architecture and for general cell health. The addition of FGF23 and soluble αKlotho to this network establishes a new conceptual framework for understanding the pathogenesis of genetic and acquired phosphate disorders. The manipulation of NaPi-2 activity and/or expression by change in FGF23 and/or αKlotho axis signal activity as well as modification of PTH and 1,25-(OH) 2 D will constitute a novel strategy for those genetic and acquired hyper-or hypophosphatemia and, even more importantly, to prolong human life. 
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